SG10201408789WA - Therapeutic compounds and related methods of use - Google Patents
Therapeutic compounds and related methods of useInfo
- Publication number
- SG10201408789WA SG10201408789WA SG10201408789WA SG10201408789WA SG10201408789WA SG 10201408789W A SG10201408789W A SG 10201408789WA SG 10201408789W A SG10201408789W A SG 10201408789WA SG 10201408789W A SG10201408789W A SG 10201408789WA SG 10201408789W A SG10201408789W A SG 10201408789WA
- Authority
- SG
- Singapore
- Prior art keywords
- related methods
- therapeutic compounds
- therapeutic
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29155409P | 2009-12-31 | 2009-12-31 | |
US29155009P | 2009-12-31 | 2009-12-31 | |
US29154409P | 2009-12-31 | 2009-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201408789WA true SG10201408789WA (en) | 2015-02-27 |
Family
ID=44226819
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012041323A SG181523A1 (en) | 2009-12-31 | 2010-12-30 | Therapeutic compounds and related methods of use |
SG10201408789WA SG10201408789WA (en) | 2009-12-31 | 2010-12-30 | Therapeutic compounds and related methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012041323A SG181523A1 (en) | 2009-12-31 | 2010-12-30 | Therapeutic compounds and related methods of use |
Country Status (28)
Country | Link |
---|---|
US (3) | US9073890B2 (en) |
EP (2) | EP3056207B1 (en) |
JP (3) | JP5753194B2 (en) |
KR (1) | KR20120115350A (en) |
CN (2) | CN102883723B (en) |
AR (1) | AR079814A1 (en) |
AU (2) | AU2010339423C1 (en) |
BR (1) | BR112012016392A2 (en) |
CA (1) | CA2785923C (en) |
CO (1) | CO6571895A2 (en) |
CY (1) | CY1118249T1 (en) |
DK (1) | DK2521549T3 (en) |
EA (2) | EA201790962A1 (en) |
ES (1) | ES2598577T3 (en) |
HK (1) | HK1173654A1 (en) |
HR (1) | HRP20161330T1 (en) |
HU (1) | HUE030752T2 (en) |
IL (1) | IL219974A0 (en) |
LT (1) | LT2521549T (en) |
MX (2) | MX349476B (en) |
MY (1) | MY161082A (en) |
PH (1) | PH12015502823A1 (en) |
PL (1) | PL2521549T3 (en) |
PT (1) | PT2521549T (en) |
SG (2) | SG181523A1 (en) |
SI (1) | SI2521549T1 (en) |
TW (2) | TWI591063B (en) |
WO (1) | WO2011082337A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2772642C (en) | 2009-09-03 | 2017-08-29 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
DE112010005848B4 (en) * | 2010-09-06 | 2016-03-10 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | amide compounds |
JP2014522837A (en) * | 2011-06-29 | 2014-09-08 | 大塚製薬株式会社 | Quinazolines as therapeutic compounds and related methods of use |
JP6121658B2 (en) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | Therapeutic compounds and related methods of use |
WO2013004652A1 (en) * | 2011-07-04 | 2013-01-10 | Bayer Intellectual Property Gmbh | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants |
WO2013013614A1 (en) * | 2011-07-28 | 2013-01-31 | 南京英派药业有限公司 | 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof |
WO2013182580A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
SI2858987T1 (en) | 2012-06-11 | 2018-06-29 | Bristol-Myers Squibb Company | Phosphoramidic acid prodrugs of 5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide |
CN102702116B (en) * | 2012-06-13 | 2014-12-31 | 华南理工大学 | 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof |
EP2970199A1 (en) | 2013-03-11 | 2016-01-20 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
CN105407894A (en) | 2013-03-14 | 2016-03-16 | 康威基内有限公司 | Methods and compositions for inhibition of bromodomain-containing proteins |
JP6139789B2 (en) * | 2013-10-16 | 2017-05-31 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | Fused heterocyclic compounds, methods for their preparation, pharmaceutical compositions and uses thereof |
PL3089971T3 (en) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Compounds and methods of use |
JP2018509377A (en) * | 2014-12-05 | 2018-04-05 | サウザーン リサーチ インスチチュート | Heterocyclic compounds as biogenic amine transport modulators |
WO2016100347A2 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of Michigan | Small molecule inhibitors of egfr and pi3k |
ES2918589T3 (en) * | 2015-11-25 | 2022-07-19 | Convergene Llc | Bicyclic BET bromodome inhibitors and uses thereof |
CN109476641B (en) * | 2016-05-24 | 2022-07-05 | 基因泰克公司 | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer |
CN107722012B (en) * | 2016-08-11 | 2020-05-29 | 斯福瑞(南通)制药有限公司 | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines |
CA3046997A1 (en) | 2016-12-13 | 2018-06-21 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
US20180193283A1 (en) | 2016-12-20 | 2018-07-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
JOP20190151B1 (en) | 2016-12-20 | 2023-09-17 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
AR112027A1 (en) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | ALK 2 KINASE INHIBITORS CONTAINING IMIDAZOLE |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
JP2020530000A (en) * | 2017-08-02 | 2020-10-15 | ノースウエスタン ユニバーシティ | Substituent condensation pyrimidine compounds and their use |
MX2020005517A (en) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Crystal forms and production methods thereof. |
US10369134B2 (en) | 2017-12-05 | 2019-08-06 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
BR112020026099A2 (en) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | transdermal therapeutic system containing asenapine |
MX2021000841A (en) | 2018-07-26 | 2021-03-26 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4. |
WO2020132409A1 (en) * | 2018-12-20 | 2020-06-25 | Trustees Of Boston University | Stk19 inhibitors for treatment of cancer |
KR20220018004A (en) | 2019-06-04 | 2022-02-14 | 선오비온 파마슈티컬스 인코포레이티드 | Controlled release formulations and uses thereof |
BR112022025037A2 (en) | 2020-06-10 | 2023-02-14 | Aligos Therapeutics Inc | ANTIVIRAL COMPOUNDS TO TREAT CORONAVIRUS, PICORNAVIRUS AND NOROVIRUS INFECTIONS |
IL303965A (en) | 2020-12-22 | 2023-08-01 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
IL309732A (en) | 2021-07-09 | 2024-02-01 | Aligos Therapeutics Inc | Anti-viral compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2657760B2 (en) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4-aminoquinazoline derivatives and pharmaceuticals containing them |
US20020025968A1 (en) * | 1998-04-15 | 2002-02-28 | Rifat Pamukcu | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives |
CN100345830C (en) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | Condensed heteroaryl derivatives |
WO2002062767A1 (en) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Novel quinazoline derivatives |
AR035791A1 (en) | 2001-03-23 | 2004-07-14 | Bayer Corp | COMPOUND N, N-DIHETEROCICLICO OF AMINA, INHIBITOR OF THE RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE COMPOUND |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
TW200406390A (en) * | 2002-01-17 | 2004-05-01 | Neurogen Corp | Substituted quinazolin-4-ylamine analogues |
JP2006515846A (en) * | 2002-12-13 | 2006-06-08 | ニューロジェン・コーポレーション | 2-Substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
US20040142958A1 (en) | 2002-12-13 | 2004-07-22 | Neurogen Corporation | Combination therapy for the treatment of pain |
WO2004065392A1 (en) * | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
CL2004000409A1 (en) | 2003-03-03 | 2005-01-07 | Vertex Pharma | COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU |
EP1610774A4 (en) * | 2003-04-09 | 2008-07-16 | Exelixis Inc | Tie-2 modulators and methods of use |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
BRPI0415683A (en) | 2003-11-03 | 2006-12-19 | Warner Lambert Co | norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
BRPI0416740A (en) | 2003-12-08 | 2007-01-16 | Pfizer | nmda receptor interaction with protein tyrosine phosphatase step in psychotic disorders |
AU2005232745A1 (en) * | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US20060128702A1 (en) | 2004-11-23 | 2006-06-15 | Manojit Pal | Heterocyclic and bicyclic compounds, compositions and methods |
JP2007084494A (en) | 2005-09-22 | 2007-04-05 | Oncorex Inc | Pim-1 activity inhibitor |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
EP1966184B1 (en) | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Pyridinyl-quinazoline derivatives and their medical use |
EP1981525B1 (en) | 2005-12-30 | 2015-01-21 | Zensun (Shanghai) Science and Technology Limited | Extended release of neuregulin for improved cardiac function |
DE102006012251A1 (en) | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments |
WO2007133773A2 (en) | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc | Identification of cdki pathway inhibitors |
GB0724349D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Antibacterial agents |
WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
WO2008092862A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
EP2142546B1 (en) * | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
US20100105705A1 (en) | 2007-03-28 | 2010-04-29 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
WO2009000085A1 (en) | 2007-06-27 | 2008-12-31 | Painceptor Pharma Corporation | Quinoline and quinazoline derivatives useful as modulators of gated ion channels |
US7893059B2 (en) | 2007-09-24 | 2011-02-22 | Genentech, Inc. | Thiazolopyrimidine PI3K inhibitor compounds and methods of use |
WO2009097446A1 (en) * | 2008-01-30 | 2009-08-06 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
EP2445346A4 (en) | 2009-06-24 | 2012-12-05 | Genentech Inc | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
WO2010151799A2 (en) | 2009-06-26 | 2010-12-29 | University Of Massachusetts | Compounds for modulating rna binding proteins and uses therefor |
WO2011019780A1 (en) | 2009-08-11 | 2011-02-17 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
CA2772642C (en) * | 2009-09-03 | 2017-08-29 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
JP5598775B2 (en) | 2009-11-02 | 2014-10-01 | ソン,ジャシェン | Pharmaceutical composition comprising ITE and its analogues for interventional treatment and eradication of cancer |
-
2010
- 2010-12-29 AR ARP100105018A patent/AR079814A1/en unknown
- 2010-12-30 JP JP2012547310A patent/JP5753194B2/en not_active Expired - Fee Related
- 2010-12-30 EA EA201790962A patent/EA201790962A1/en unknown
- 2010-12-30 TW TW099146921A patent/TWI591063B/en not_active IP Right Cessation
- 2010-12-30 US US13/520,018 patent/US9073890B2/en not_active Expired - Fee Related
- 2010-12-30 EP EP16159344.7A patent/EP3056207B1/en not_active Not-in-force
- 2010-12-30 SG SG2012041323A patent/SG181523A1/en unknown
- 2010-12-30 BR BR112012016392A patent/BR112012016392A2/en not_active IP Right Cessation
- 2010-12-30 MX MX2015012332A patent/MX349476B/en unknown
- 2010-12-30 WO PCT/US2010/062555 patent/WO2011082337A1/en active Application Filing
- 2010-12-30 SG SG10201408789WA patent/SG10201408789WA/en unknown
- 2010-12-30 HU HUE10841742A patent/HUE030752T2/en unknown
- 2010-12-30 DK DK10841742.9T patent/DK2521549T3/en active
- 2010-12-30 EP EP10841742.9A patent/EP2521549B1/en not_active Not-in-force
- 2010-12-30 EA EA201290593A patent/EA028066B1/en not_active IP Right Cessation
- 2010-12-30 CN CN201080060265.0A patent/CN102883723B/en not_active Expired - Fee Related
- 2010-12-30 ES ES10841742.9T patent/ES2598577T3/en active Active
- 2010-12-30 CN CN201510562796.4A patent/CN105218516A/en active Pending
- 2010-12-30 MX MX2012007727A patent/MX2012007727A/en active IP Right Grant
- 2010-12-30 LT LTEP10841742.9T patent/LT2521549T/en unknown
- 2010-12-30 PT PT108417429T patent/PT2521549T/en unknown
- 2010-12-30 KR KR1020127020038A patent/KR20120115350A/en active IP Right Grant
- 2010-12-30 CA CA2785923A patent/CA2785923C/en not_active Expired - Fee Related
- 2010-12-30 TW TW105116505A patent/TWI601723B/en not_active IP Right Cessation
- 2010-12-30 AU AU2010339423A patent/AU2010339423C1/en not_active Ceased
- 2010-12-30 SI SI201031302A patent/SI2521549T1/en unknown
- 2010-12-30 PL PL10841742T patent/PL2521549T3/en unknown
- 2010-12-30 MY MYPI2012002782A patent/MY161082A/en unknown
-
2012
- 2012-05-24 IL IL219974A patent/IL219974A0/en unknown
- 2012-07-31 CO CO12128701A patent/CO6571895A2/en active IP Right Grant
-
2013
- 2013-01-16 HK HK13100713.1A patent/HK1173654A1/en not_active IP Right Cessation
-
2015
- 2015-04-21 US US14/692,434 patent/US9630947B2/en active Active
- 2015-05-20 JP JP2015102620A patent/JP6062999B2/en not_active Expired - Fee Related
- 2015-12-18 PH PH12015502823A patent/PH12015502823A1/en unknown
-
2016
- 2016-10-12 HR HRP20161330TT patent/HRP20161330T1/en unknown
- 2016-10-19 CY CY20161101048T patent/CY1118249T1/en unknown
- 2016-12-14 JP JP2016242519A patent/JP2017071639A/en active Pending
-
2017
- 2017-02-22 AU AU2017201175A patent/AU2017201175A1/en not_active Abandoned
- 2017-03-13 US US15/456,927 patent/US20170217923A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1173654A1 (en) | Therapeutic compounds and related methods of use | |
EP2448581A4 (en) | Therapeutic compositions and related methods of use | |
HK1211889A1 (en) | Therapeutic use of diaminophenothiazines | |
HK1172896A1 (en) | Compounds and methods of use | |
HK1161094A1 (en) | Compounds and methods of use | |
IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
EP2464227A4 (en) | Compounds and methods of use thereof | |
ZA201106730B (en) | Methods of treatment using combination therapy | |
IL236830A0 (en) | Diazahomoadamantane derivatives and methods of use thereof | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
ZA201201287B (en) | Therapeutic aryl-amido-aryl compounds and their use | |
ZA201205057B (en) | Fungicidal compounds and methods of their use | |
GB201011411D0 (en) | Therapeutic compounds and their use | |
EP2406244A4 (en) | Estrogenic compounds and their methods of use | |
EP2440238A4 (en) | Methods of treatment | |
GB0913300D0 (en) | Therapeutic compounds and their use | |
HK1174620A1 (en) | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | |
GB201009614D0 (en) | Therapeutic use of compounds | |
GB0819854D0 (en) | Therapeutic use of zolpidem | |
GB0809936D0 (en) | Therapeutic use of zolpidem | |
GB201019938D0 (en) | Determination of therapeutic agents | |
GB201004480D0 (en) | Therapeutic use of new compounds II |